Date: 2012-09-25
Type of information: Grant
Company: ExpreS2ion (Denmark) Mucosis (The Netherlands)
Investors: European Eurostars Programme (EU)
Amount: € 1 million
Funding type: grant
Planned used: This grant will be used to fund the pre-clinical development of a placental malaria vaccine.
Others: ExpreS2ion Biotechnologies and Mucosis, along with University of Copenhagenhave been awarded a Eurostars grant with a total budget of over €1 million for the pre-clinical development of an innovative placental malaria vaccine. This collaboration will apply novel vaccine technologies developed at Mucosis and ExpreS2ion to a malaria antigen developed at University of Copenhagen in a project funded by The Danish National Advanced Technology Foundation. This vaccine development program aims to provide women in high-risk areas lifelong protection against malaria infection.
Mucosis B.V. is a clinical-stage Dutch biotechnology company with a proprietary platform technology, Mimopath®, on which it develops mucosal vaccines with improved efficacy.
ExpreS2ion Biotechnologies has developed a complete proprietary protein expression platform, ExpreS2, based on engineered Drosophila Schneider-2 (S2) cells, to serve recombinant protein production needs of research teams and recombinant subunit vaccine developers. ExpreS2 allows quick access to proteins, excellent protein expression capability, scalability, applicability to high cell density production processes and regulatory friendliness.
Therapeutic area: Infectious diseases
